bioRxiv · 10.1101/2025.11.26.690143
U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis
Abstract
TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth. We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons, and shows target engagement in vivo, positioning tU7-mediated splicing correction as a promising therapeutic strategy for ALS.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mehta, P. R., Solomon, T., Pickles, S., Harley, P., Barioglio, M., Schweingruber, C., Marrero-Gagliardi, A., Gao, Y., Mattedi, F., Barattucci, S., Lin, L. T.-W., Ryadnov, E., Zanovello, M., Cammack, A. J., Isaacs, A., Burrone, J., Shaw, C. E., Keuss, M. J., Petrucelli, L., Fratta, P., Ruepp, M.-D.. 2025-11-30. U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis. https://doi.org/10.1101/2025.11.26.690143
Cite the original work for its findings. Save a collection to share your selection of sources.